Evidence mapPaperPMID 42009997Full record

ReviewInflammopharmacology2026

Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.

Mahendra Pratap Swain, Chetan Hasmukh Mehta, Bhrath Singh Padya, Shreya Sharma, Varalakshmi Velagacherla, Adwitiya Mitra, Satyajit Mohanty, Tuhin Mukherjee

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mahendra Pratap SwainDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India. mahendrapratapswain1994@gmail.com.ORCID http://orcid.org/0000-0002-7941-3064
Chetan Hasmukh MehtaManipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Bhrath Singh PadyaManipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Shreya SharmaDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.
Varalakshmi VelagacherlaManipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Adwitiya MitraWipro Technologies, Bidhannagar, Kolkata, 700091, India.
Satyajit MohantyTeam Photonics & Metabolics, Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India. satyajitmohanty922@gmail.com.ORCID http://orcid.org/0000-0001-6665-3432
Tuhin MukherjeeTeam Photonics & Metabolics, Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human microbiome has an enormous and multifaceted ecosystem of microorganisms like fungi, protozoa, bacteria, and viruses that live in our bodies, mainly in the gut, and is crucial in maintaining our health. The published evidence supports that they influence gut and brain health. Over the past decade, research has brought to light the possibility that diseases commonly found in the Western world, like type II diabetes, obesity, and inflammatory bowel disease (IBD), might be treatable through microbiome-modulating therapeutic interventions. This review discusses the emerging microbiome-targeted interventions and their therapeutic potential and mechanisms of action. Microbiota-based therapeutics for IBD can help to mitigate inflammation and restore the balance of microbes, utilizing a variety of inputs such as probiotics and fecal microbiota transplants (FMT). For example, the modification of gut microbiome has been accompanied by positive effects on insulin sensitivity and glycemic control in diabetes, and in other studies with type 2 diabetes, dietary interventions or prebiotic supplementation appeared to provide beneficial outcomes as well. The treatment of obesity has also significantly increased with methods of microbiome manipulation intertwined with the regulation of energy homeostasis and fat storage. Here, we review the progress of the advancement of different approaches to modulate gut microbiome, including probiotics, prebiotics, and FMT, and more specifically, we consider how these therapies affect gut microbial flora balance and function. Therefore, in addition to alleviating symptoms, these treatments may help change the underlying processes of illness. Future research endeavors include enhancing the effectiveness of these medicines by comprehensively studying individual microbiome differences and using tailored techniques. The current exploration of the gut microbiome has substantial potential for pioneering therapies, establishing a foundation for forthcoming advancements in managing chronic illnesses via manipulating the microbiome.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaAnimalsChronic DiseaseDiabetes Mellitus, Type 2Fecal Microbiota TransplantationHumansInflammatory Bowel DiseasesObesityPrebioticsProbioticsPrebioticsChronic diseasesFaecal microbiota transplant (FMT)Gut healthInflammatory bowel disease (IBD)Microbial balanceMicrobiome-modulating therapiesObesity managementPrebioticsProbioticsType II diabetes

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.